← All trials
NCT06103825
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Oct 20, 2024
- First posted
- Oct 27, 2023
- Last posted
- Oct 27, 2023
- Enrollment
- 204
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ignis Therapeutics (Suzhou) LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.